In recent decades, therapeutic strategies targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations have made it possible to achieve substantial advances in the treatment of NSCLC patients [107]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.